13F HOLDINGS REPORT
Foresite Capital Management IV, LLC
Quarter ended Q1 2023 · Filed February 13, 2023 · Accession 0001104659-23-019778
Total Value
$234.1M
Positions
8
Other Managers
0
Confidential Omitted
No
Holdings (8)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Kinnate Biopharma Inc. | 49705R105 | 9,671,643 | $59.0M | 25.20% |
| 2 | Aclaris Therapeutics, Inc. | ACRS | 2,808,034 | $44.2M | 18.89% |
| 3 | Pharvaris N.V. | PHVS | 3,246,926 | $36.5M | 15.60% |
| 4 | Lyell Immunopharma, Inc. | LYEL | 10,000,000 | $34.7M | 14.82% |
| 5 | Kura Oncology, Inc. | KURA | 1,849,947 | $23.0M | 9.81% |
| 6 | Syndax Pharmaceuticals, Inc. | SNDX | 875,000 | $22.3M | 9.51% |
| 7 | Cymabay Therapeutics, Inc. | 23257D103 | 1,787,094 | $11.2M | 4.79% |
| 8 | Quantum-Si Incorporated | QSIAW | 1,771,249 | $3.2M | 1.38% |